SCHEMBL4227353

SCHEMBL4227353

CCOC(=O)c1ccc(C(Cc2cccc(N)n2)c2cccc(N)n2)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 4/20 0.47
ALDH1A1 P00352 4/20 0.47
NPC1 O15118 3/20 0.47
MAPT P10636 3/20 0.47
PKM P14618 1/20 0.47
NPSR1 Q6W5P4 1/20 0.47
TDP1 Q9NUW8 1/20 0.47
CYP1A2 P05177 2/20 0.45
LMNA P02545 1/20 0.45
CYP3A4 P08684 1/20 0.45
MAOA P21397 1/20 0.45
PARP1 P09874 1/20 0.40
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40
CA12 O43570 1/20 0.40
CA1 P00915 1/20 0.40
CA2 P00918 1/20 0.40
ESR1 P03372 1/20 0.40
CA7 P43166 1/20 0.40
CA9 Q16790 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3885745 0.84 CPB2 (0.43) ALDH1A1CPB2KDM4EBACE1
Hydrochloric Acid SCHEMBL6224043 0.83 CPB2 (0.43) CPB2BACE1
SCHEMBL5260948 0.76 NPC1 (0.53) RAB9AALDH1A1NPC1MAPTPKM
SCHEMBL3016243 0.71 BACE1 (0.70) RAB9AALDH1A1NPC1MAPTPKM
SCHEMBL19359313 0.71 SMN1; SMN2 (0.50) RAB9AALDH1A1NPC1MAPTPKM
SCHEMBL28671126 0.70 CPB2 (0.47) RAB9AALDH1A1NPC1MAPTPKM
Benzene SCHEMBL27873122 0.69 CA1 (0.76) RAB9AALDH1A1NPC1MAPTNPSR1
SCHEMBL5795560 0.68 MAPT (0.46) RAB9AALDH1A1NPC1MAPTPKM
SCHEMBL9678668 0.68 LMNA (0.57) RAB9AALDH1A1NPC1MAPTCYP1A2
SCHEMBL5693092 0.68 CHEK1 (0.50) RAB9AALDH1A1NPC1MAPTPKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1047425-A4 INTEGRIN RECEPTOR ANTAGONISTS MERCK & CO INC (US) 2009-04-22 EP disclosed
EP-1331937-A4 DIBENZOXAZEPINE ALPHA V INTEGRIN RECEPTOR ANTAGONIST MERCK & CO INC (US) 2004-07-21 EP disclosed
EP-1331937-A2 DIBENZOXAZEPINE ALPHA V INTEGRIN RECEPTOR ANTAGONIST Merck & Co., Inc. (US) 2003-08-06 EP disclosed
EP-1319002-A1 ALPHA V INTEGRIN RECEPTOR ANTAGONISTS Merck & Co., Inc. (US) 2003-06-18 EP disclosed
EP-1007026-A4 INTEGRIN ANTAGONISTS MERCK & CO INC (US) 2002-08-07 EP disclosed
WO-2002040505-A2 DIBENZOXAZEPINE ALPHA V INTEGRIN RECEPTOR ANTAGONIST MERCK & CO., INC. (US) 2002-05-23 WO disclosed
WO-2002022615-A1 ALPHA V INTEGRIN RECEPTOR ANTAGONISTS MERCK & CO., INC. (US) 2002-03-21 WO disclosed
WO-2002022616-A2 ALPHA V INTEGRIN RECEPTOR ANTAGONISTS MERCK & CO., INC. (US) 2002-03-21 WO disclosed
EP-0934305-A4 INTEGRIN ANTAGONISTS MERCK & CO INC (US) 2001-04-11 EP disclosed
EP-0946165-A4 INTEGRIN ANTAGONISTS MERCK & CO INC (US) 2001-04-11 EP disclosed
EP-0946165-A1 INTEGRIN ANTAGONISTS Merck & Co., Inc. (US) 1999-10-06 EP disclosed
EP-0934305-A1 INTEGRIN ANTAGONISTS Merck & Co., Inc. (US) 1999-08-11 EP disclosed
WO-1999030709-A1 INTEGRIN RECEPTOR ANTAGONISTS MERCK & CO., INC. (US) 1999-06-24 WO disclosed
WO-1999031061-A1 INTEGRIN RECEPTOR ANTAGONISTS MERCK & CO., INC. (US) 1999-06-24 WO disclosed
WO-1999031099-A1 INTEGRIN RECEPTOR ANTAGONISTS MERCK & CO., INC. (US) 1999-06-24 WO disclosed
WO-1998046220-A1 COMBINATION THERAPY FOR THE PREVENTION AND TREATMENT OF OSTEOPOROSIS MERCK & CO., INC. (US) 1998-10-22 WO disclosed
WO-1998044797-A1 A METHOD OF TREATING CANCER MERCK & CO., INC. (US) 1998-10-15 WO disclosed
WO-1998031359-A1 INTEGRIN ANTAGONISTS MERCK & CO., INC. (US) 1998-07-23 WO disclosed
WO-1998018460-A1 INTEGRIN ANTAGONISTS MERCK & CO., INC. (US) 1998-05-07 WO disclosed
WO-1998008840-A1 INTEGRIN ANTAGONISTS MERCK & CO., INC. (US) 1998-03-05 WO disclosed